{"id":478210,"date":"2020-04-07T11:50:01","date_gmt":"2020-04-07T11:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=478210"},"modified":"2020-04-07T11:50:01","modified_gmt":"2020-04-07T11:50:01","slug":"lupus-nephritis-market-analysis-market-size-epidemiology-leading-companies-and-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lupus-nephritis-market-analysis-market-size-epidemiology-leading-companies-and-forecast_478210.html","title":{"rendered":"Lupus Nephritis Market Analysis, Market Size, Epidemiology, Leading Companies and Forecast"},"content":{"rendered":"
\"Lupus<\/a><\/p>\n
\n
“Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030”<\/div>\n<\/div>\n<\/div>\n

DelveInsight launched a new report on “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030<\/a>”.<\/p>\n

DelveInsight’s “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030″<\/strong> report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the facts of the report<\/strong><\/p>\n

1. As per DelveInsight analysis, the United Sates accounted for the maximum number of LN patients with 134,190 cases in 2017.<\/p>\n

2. As per DelveInsight analysis, Italy accounted for 134,190 LN patients in 2017.<\/p>\n

3. DelveInsight estimates, in 2017, Proteinuria associated with LN cases were found in all of the diagnosed cases, while second common manifestation in LN was microscopic hematuria with 85,882 cases (80%).<\/p>\n

4. As per DelveInsight’s estimates, total Prevalent population of Lupus Nephritis in the 7 major markets was 190,819 in 2017,<\/p>\n

Key benefits of the report<\/strong><\/p>\n

1. Lupus Nephritis market report covers a descriptive overview and comprehensive insight of the Lupus Nephritis epidemiology and Lupus Nephritis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Lupus Nephritis market report provides insights on the current and emerging therapies.
3. Lupus Nephritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. Lupus Nephritis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Lupus Nephritis market.<\/p>\n

Request for sample pages :<\/strong> https:\/\/delveinsight.com\/sample-request\/lupus-nephritis-market<\/a><\/p>\n

 <\/p>\n

“According to Delveinsight,<\/em><\/strong> Market Size of Lupus Nephritis (LN) in the 7MM was found to be $1360million in 2017.”
<\/em><\/strong>
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is being characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations.<\/p>\n

The primary pathological findings in patients with SLE include inflammation, vasculitis, immune complex deposition, and vasculopathy.<\/p>\n

Lupus nephritis (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.<\/p>\n

Although LN can occur during a flare of SLE with skin manifestations or other organ system involvement, it often occurs without other clinical signs of active lupus. Thus, it is of key importance that patients with lupus have routine urine analysis with microscopy looking for protein, blood, and cellular casts. Lupus nephritis is primarily caused by the deposition of immune complexes. The size of the complexes determines the location of deposition, and therefore, leads to differences in classification (mesangial, focal, diffuse).<\/p>\n

The launch of the emerging therapies is expected to significantly impact Lupus nephritis treatment scenario in the upcoming years:-
Drugs covered<\/strong><\/p>\n

    \n
  1. Prograf<\/li>\n
  2. Obinutuzumab<\/li>\n
  3. Belimumab<\/li>\n
  4. Voclosporin<\/li>\n
  5. Anifrolumab<\/li>\n
  6. BI 655064<\/li>\n
  7. Iscalimab<\/li>\n<\/ol>\n

    And many others<\/p>\n

     <\/p>\n

    The key players in Lupus nephritis market are:<\/strong><\/p>\n

      \n
    1. Astellas Pharma<\/li>\n
    2. Roche<\/li>\n
    3. GlaxoSmithKline<\/li>\n
    4. Aurinia Pharmaceuticals<\/li>\n
    5. AstraZeneca<\/li>\n
    6. Boehringer Ingelheim<\/li>\n
    7. Novartis<\/li>\n<\/ol>\n

      And many others<\/p>\n

       <\/strong><\/p>\n

      Request for sample pages :<\/strong> https:\/\/delveinsight.com\/sample-request\/lupus-nephritis-market<\/a><\/p>\n

      Table of contents<\/strong><\/p>\n

      1. Key Insights<\/strong><\/p>\n

      2. Executive Summary of Lupus Nephritis<\/strong><\/p>\n

      3. Competitive Intelligence Analysis for Lupus Nephritis<\/strong><\/p>\n

      4. Lupus Nephritis: Market Overview at a Glance<\/strong><\/p>\n

      4.1. Lupus Nephritis Total Market Share (%) Distribution in 2017<\/p>\n

      4.2. Lupus Nephritis Total Market Share (%) Distribution in 2030<\/p>\n

      5. Lupus Nephritis: Disease Background and Overview<\/strong><\/p>\n

      5.1. Introduction<\/p>\n

      5.2. Sign and Symptoms <\/p>\n

      5.3. Pathophysiology <\/p>\n

      5.4. Risk Factors <\/p>\n

      5.5. Diagnosis <\/p>\n

      6. Patient Journey<\/strong><\/p>\n

      7. Lupus Nephritis Epidemiology and Patient Population<\/strong><\/p>\n

      7.1. Epidemiology Key Findings<\/p>\n

      7.2. Assumptions and Rationale: 7MM<\/p>\n

      7.3. Epidemiology Scenario: 7MM<\/p>\n

      7.3.1. Lupus Nephritis Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n

      7.4. United States Epidemiology<\/p>\n

      7.4.1. Lupus Nephritis Epidemiology Scenario in the United States (2017-2030)<\/p>\n

      7.5. EU-5 Country-wise Epidemiology<\/p>\n

      7.5.1. Germany Epidemiology<\/p>\n

      7.5.1.1. Lupus Nephritis Epidemiology Scenario in Germany (2017-2030)<\/p>\n

      7.5.2. France Epidemiology<\/p>\n

      7.5.2.1. Lupus Nephritis Epidemiology Scenario in France (2017-2030)<\/p>\n

      7.5.3. Italy Epidemiology<\/p>\n

      7.5.3.1. Lupus Nephritis Epidemiology Scenario in Italy (2017-2030)<\/p>\n

      7.5.4. Spain Epidemiology<\/p>\n

      7.5.4.1. Lupus Nephritis Epidemiology Scenario in Spain (2017-2030)<\/p>\n

      7.5.5. United Kingdom Epidemiology<\/p>\n

      7.5.5.1. Lupus Nephritis Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n

      7.5.6. Japan Epidemiology<\/p>\n

      7.5.6.1. Lupus Nephritis Epidemiology Scenario in Japan (2017-2030)<\/p>\n

      8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n

      8.1. Lupus Nephritis Treatment and Management<\/p>\n

      8.2. Lupus Nephritis Treatment Algorithm <\/p>\n

      9. Unmet Needs<\/strong><\/p>\n

      10. Key Endpoints of Lupus Nephritis Treatment<\/strong><\/p>\n

      11. Marketed Products<\/strong><\/p>\n

      11.1. List of Marketed Products in the 7MM<\/p>\n

      11.2. Drug Name: Company Name<\/p>\n

      11.2.1. Product Description<\/p>\n

      11.2.2. Regulatory Milestones<\/p>\n

      11.2.3. Other Developmental Activities<\/p>\n

      11.2.4. Pivotal Clinical Trials<\/p>\n

      11.2.5. Summary of Pivotal Clinical Trial<\/p>\n

      List to be continued in report<\/p>\n

      12. Emerging Therapies<\/strong><\/p>\n

      12.1. Key Cross<\/p>\n

      12.2. Drug Name: Company Name<\/p>\n

      12.2.1. Product Description<\/p>\n

      12.2.2. Other Developmental Activities<\/p>\n

      12.2.3. Clinical Development<\/p>\n

      12.2.4. Safety and Efficacy<\/p>\n

      12.2.5. Product Profile<\/p>\n

      List to be continued in report<\/p>\n

      13. Lupus Nephritis: Seven Major Market Analysis<\/strong><\/p>\n

      13.1. Key Findings<\/p>\n

      13.2. Lupus Nephritis Market Size in 7MM<\/p>\n

      13.3. Lupus Nephritis Market Size by Therapies in the 7MM<\/p>\n

      14. Attribute analysis<\/strong><\/p>\n

      15. 7MM: Market Outlook<\/strong><\/p>\n

      15.1. United States: Market Size<\/p>\n

      15.1.1. Lupus Nephritis Total Market Size in the United States<\/p>\n

      15.1.2. Lupus Nephritis Market Size by Therapies in the United States<\/p>\n

      15.2. EU-5 countries: Market Size and Outlook<\/p>\n

      15.3. Germany Market Size<\/p>\n

      15.3.1. Lupus Nephritis Total Market Size in Germany<\/p>\n

      15.3.2. Lupus Nephritis Market Size by Therapies in Germany<\/p>\n

      15.4. France Market Size<\/p>\n

      15.4.1. Lupus Nephritis Total Market Size in France<\/p>\n

      15.4.2. Lupus Nephritis Market Size by Therapies in France<\/p>\n

      15.5. Italy Market Size<\/p>\n

      15.5.1. Lupus Nephritis Total Market Size in Italy<\/p>\n

      15.5.2. Lupus Nephritis Market Size by Therapies in Italy<\/p>\n

      15.6. Spain Market Size<\/p>\n

      15.6.1. Lupus Nephritis Total Market Size in Spain<\/p>\n

      15.6.2. Lupus Nephritis Market Size by Therapies in Spain<\/p>\n

      15.7. United Kingdom Market Size<\/p>\n

      15.7.1. Lupus Nephritis Total Market Size in the United Kingdom<\/p>\n

      15.7.2. Lupus Nephritis Market Size by Therapies in the United Kingdom<\/p>\n

      15.8. Japan Market Outlook<\/p>\n

      15.8.1. Japan Market Size<\/p>\n

      15.8.2. Lupus Nephritis Total Market Size in Japan<\/p>\n

      15.8.3. Lupus Nephritis Market Size by Therapies in Japan<\/p>\n

      16. Access and Reimbursement Overview of Lupus Nephritis<\/strong><\/p>\n

      17. KOL Views<\/strong><\/p>\n

      18. Market Drivers<\/strong><\/p>\n

      19. Market Barriers<\/strong><\/p>\n

      20. Appendix<\/strong><\/p>\n

      20.1. Bibliography<\/p>\n

      20.2. Report Methodology<\/p>\n

      21. DelveInsight Capabilities<\/strong><\/p>\n

      22. Disclaimer<\/strong><\/p>\n

      23. About DelveInsight<\/strong><\/p>\n

      *The table of contents is not exhaustive; the final content may vary. <\/em><\/strong><\/p>\n

       <\/p>\n

      Related Reports: <\/strong><\/p>\n

      Lupus Nephritis – Pipeline Insights, 2020 <\/a><\/span><\/p>\n

      The Dry eye disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dry eye disease across the complete product development cycle, including all clinical and nonclinical stages.<\/p>\n

      Lupus Nephritis – Epidemiology Forecast to 2030<\/a><\/span><\/p>\n

      The Lupus Nephritis epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030<\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Ankit Nigam
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Albany
      State:<\/strong> New York
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030” DelveInsight launched a new report on “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030”. DelveInsight’s “Lupus Nephritis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,403,404],"tags":[],"class_list":["post-478210","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/478210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=478210"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/478210\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=478210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=478210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=478210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}